ARS Pharmaceuticals (SPRY) Change in Accured Expenses (2020 - 2026)

ARS Pharmaceuticals has disclosed Change in Accured Expenses across 7 years of filings, most recently posting $10.3 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $10.3 million, up 147.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.0 million (up 30.1% YoY), and the FY2025 annual result was $18.9 million, up 15.04% from the prior year.
• Change in Accured Expenses came in at $10.3 million for Q1 2026 at ARS Pharmaceuticals, up from -$9.1 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $12.8 million in Q2 2025 to a low of -$11.4 million in Q4 2022.
• The 5-year median for Change in Accured Expenses is $1.3 million (2024), against an average of $1.9 million.
• Across the five-year window, Change in Accured Expenses jumped 1268.75% in 2024 and slumped 218.27% in 2025, its largest moves.
• ARS Pharmaceuticals' Change in Accured Expenses stood at -$11.4 million in 2022, then increased by 22.25% to -$8.9 million in 2023, then jumped by 186.3% to $7.7 million in 2024, then plunged by 218.27% to -$9.1 million in 2025, then surged by 213.8% to $10.3 million in 2026.
• The last three Change in Accured Expenses figures came in at $10.3 million (Q1 2026), -$9.1 million (Q4 2025), and $11.0 million (Q3 2025), per Business Quant data.